Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from ArcticZymes Technologies ASA ( (DE:B4V) ).
ArcticZymes Technologies reported a 5% year-over-year increase in total revenues for Q2 2025, driven by a 52% growth in its Biomanufacturing segment. The launch of the GMP-grade M-SAN HQ product marks a strategic milestone, enhancing the company’s role in gene therapy workflows and opening new opportunities in viral vector production. Despite a temporary decline in the Molecular Tools segment, the company anticipates recovery supported by new orders. ArcticZymes continues to focus on commercial execution and sustainable growth, with expectations of continued momentum in Biomanufacturing and recovery in Molecular Tools revenues.
More about ArcticZymes Technologies ASA
ArcticZymes Technologies is a Norwegian life sciences company specializing in the development, manufacturing, and commercialization of novel recombinant enzymes for molecular research, In Vitro Diagnostics (IVD), and biomanufacturing. The company is listed on the Oslo Stock Exchange and is headquartered in Tromsø, Norway.
Average Trading Volume: 20,738
Current Market Cap: NOK978M
See more insights into B4V stock on TipRanks’ Stock Analysis page.